Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 2/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.48 |
| ▸ | FNTA | P49354 | 6/20 | 0.42 |
| ▸ | FNTB | P49356 | 6/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.40 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4966335 | 0.83 | OPRL1 (0.44) | OPRL1KCNH2FNTAFNTBP2RX7 | |
| SCHEMBL6176740 | 0.79 | FNTA (0.58) | FNTAFNTB | |
| SCHEMBL12050758 | 0.73 | P2RX7 (0.41) | OPRL1KCNH2FNTAFNTBP2RX7 | |
| SCHEMBL1978262 | 0.68 | FNTA (0.60) | FNTAFNTB | |
| SCHEMBL17549915 | 0.67 | OPRL1 (0.49) | OPRL1KCNH2P2RX7 | |
| SCHEMBL12004295 | 0.67 | HTR2C (0.45) | OPRL1KCNH2P2RX7 | |
| SCHEMBL29439759 | 0.67 | OPRL1 (0.49) | OPRL1KCNH2P2RX7 | |
| SCHEMBL18204541 | 0.67 | HTR2C (0.45) | OPRL1KCNH2P2RX7 | |
| SCHEMBL3314142 | 0.67 | OPRL1 (0.49) | OPRL1KCNH2P2RX7 | |
| SCHEMBL14289895 | 0.67 | FNTA (0.58) | FNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070213340-A1 | Farnesyl protein transferase inhibitors | SCHERING CORPORATION | 2007-09-13 | — | — | US | disclosed |
| US-20070213340-A1 | Farnesyl protein transferase inhibitors | SCHERING CORPORATION | 2007-09-13 | — | — | US | disclosed |
| WO-2007084498-A1 | PIPERAZINE DERIVATIVES AS FARNESYL PROTEIN TRANSFERASE INHIBITORS | SCHERING CORPORATION (US) | 2007-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213340-A1 | Farnesyl protein transferase inhibitors | FNTB, FNTA, FDPS | OPRL1 4759/4885KCNH2 4745/4885FNTA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.